03681 SINOMAB BIO-B
- 1.050
- +0.020+1.94%
SINOMAB BIO-B News
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
China Antibody-B (03681) and New Brightness-B (01952) have made progress in authorized cooperation, and the new BTK inhibitor SN1011 has achieved positive results in the phase 1b/2a clinical trial interim data.
This milestone result not only recognizes the huge potential of SN1011, but also marks an important milestone achievement in the authorized cooperation agreement between China Antibody and Yunding Xinyao.
China Antibody-B (03681.HK) granted 10.0624 million share options to director Wang Shanchun.
Granolith November 11th | China Antibody-B (03681.HK) announced that on November 11, 2024, the company has granted Wang Shanchun, an executive director, 10.0624 million share options under its share purchase plan, for subscription of a total of 10.0624 million new company shares.
China antibody-B (03681): Director Liu Wenyi resigns as non-executive director
China Antibody-B (03681) announced that Liu Wenyi has resigned as a non-executive director, effective September 2024...
SINOMAB BIO-B: Interim Report 2024
Some biomedical stocks rise, Akeso (09926) rises 13.9%, institutions indicate that the sector's fundamentals are gradually bottoming out and stabilizing.
Golden Finance News | Some biomedical stocks rose, with Akeso (09926) up 13.9%, Sanpower Medical (02257) up 5.47%, China Antibody (03681) up 4.35%, GL Pharm (01672) up 4.12%, Viva Biotech (01873) up 3.45%, Wuxi AppTec (02359) up 2.6%, Wuxi Bio (02269) up 1.27%. China Post Securities expressed that the overall revenue growth rate of the biomedical sector compared to the same period last year is -1.26%, lower than Q1 growth rate, mainly due to vaccines (-32.75%), and CXO (-9.45%).
Have Insiders Sold SinoMab BioScience Shares Recently?
SinoMab BioScience's H1 Loss Narrows as Revenue Rises; Shares Fall 15%
China Antibody-B (03681) released its interim performance with a revenue of 2.026 million yuan, a year-on-year increase of 48.4%.
China Antibody-B (03681) released its six-month performance ending on June 30, 2024, with revenue of 202.6 million...
China Antibody-B (03681.HK) reduced its mid-year losses to 90.6 million yuan.
On August 19th, Gelonghui announced that as of June 30th, 2024, the total amount of other income and gains reported by the company for the six-month period was approximately RMB 43 million, a decrease of approximately RMB 28 million from the same period last year, mainly due to a reduction in government subsidies of approximately RMB 23 million. The loss for the period decreased by RMB 43.5 million, from RMB 134.1 million in the same period last year to RMB 90.6 million in the current period, mainly due to (i) the BLA acceptance of Syzilumab in September 2023 and (ii) the launch of Syzilumab in 2024.
Express News | SinoMab BioScience - Hy Revenue RMB2 Mln Vs RMB1.4 Mln
Express News | SinoMab BioScience Ltd - Hy Loss RMB90.6 Mln
SINOMAB BIO-B: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED 30 JUNE 2024AND CHANGE IN USE OF PROCEEDS
Hang Seng Index: Benefiting from policy support, biotechnology stocks have seen three consecutive months of inflows.
The Hang Seng Index company stated that there are signs of improvement in the recent situation of biotechnology stocks, as well as benefitting from policy support and three consecutive months of inflow of funds.
China Antibody-B (03681.HK) plans to hold a board of directors meeting on August 19 to approve its mid-term performance.
China Antibody-B (03681.HK) announced that the board of directors has scheduled a board meeting on Monday, August 19, 2024 to consider and approve the group's interim performance for the six months ending June 30, 2024, as well as to handle other matters.
Sinomab Bioscience Administers First Dose of Atopic Dermatitis Drug
SinoMab Doses First Patient in Clinical Study of Atopic Dermatitis Drug in China
China Antibody-B (03681): The first patient in the Phase 1b clinical trial in China was treated with SM17.
China Antibody-B (03681) issued a notice on June 5, 2024, regarding the treatment of atopic dermatitis with SM17...
SINOMAB BIO-B: Annual Report 2023
No Data
